These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
253 related items for PubMed ID: 2974348
21. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias]. Goranov I, Naumova R, Kerekovska M, Balabanski L. Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738 [Abstract] [Full Text] [Related]
22. [Nutrition and plasma apoproteins B and A-I]. Khaltaev NG, Perova NV, Dobordzhginidze LM, Metel'skaia VA, Grishenkov EA. Ter Arkh; 1987; 59(5):108-12. PubMed ID: 3112987 [No Abstract] [Full Text] [Related]
26. [Bezalip in the treatment of hyperlipoproteinemia]. Ceska R, Sobra J, Procházková P, Kvasilová M. Cas Lek Cesk; 1990 Jan 05; 129(1):20-2. PubMed ID: 2331712 [Abstract] [Full Text] [Related]
27. Hypolipidemic effects of bezafibrate: studies in Italy. Postiglione A, Riccardi G, Saldalamacchia G. Monogr Atheroscler; 1986 Jan 05; 14():198-202. PubMed ID: 3526125 [No Abstract] [Full Text] [Related]
28. Gemfibrozil in hyperlipidaemia: an open, single blind trial. Varthakavi PK, Turakhia DP, Sharma SS, Salgaonkar DS, Nihalani KD, Joshi VR. J Assoc Physicians India; 1990 Feb 05; 38(2):136-40. PubMed ID: 2380132 [Abstract] [Full Text] [Related]
30. [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. Julius U, Hora C, Gross P, Fücker K, Bergmann S, Hanefeld M. Fortschr Med; 1992 Dec 20; 110(35-36):669-72. PubMed ID: 1487226 [Abstract] [Full Text] [Related]
31. [Long-term effects of a glycosaminoglycan on plasma lipids]. Avogaro P, Bittolo-Bon G, Alessandrini P. Clin Ter; 1981 Jul 15; 98(1):47-61. PubMed ID: 7249572 [No Abstract] [Full Text] [Related]
32. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate]. Uglesić A, Ljachnicky N. Schweiz Rundsch Med Prax; 1988 Jul 05; 77(27-28):755-61. PubMed ID: 3041534 [No Abstract] [Full Text] [Related]
33. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Franceschini G, Sirtori M, Gianfranceschi G, Frosi T, Montanari G, Sirtori CR. Artery; 1985 Jul 05; 12(6):363-81. PubMed ID: 4051756 [Abstract] [Full Text] [Related]
35. Biochemical, clinical, epidemiologic, genetic, and pathologic data in the pediatric age group relevant to the cholesterol hypothesis. Kwiterovich PO. Pediatrics; 1986 Aug 05; 78(2):349-62. PubMed ID: 3090513 [No Abstract] [Full Text] [Related]
36. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia]. Bolzano K, Krempler F, Schellenberg B, Schlierf G. Acta Med Austriaca; 1979 Aug 05; 6(3):90-4. PubMed ID: 547652 [Abstract] [Full Text] [Related]
37. [Biochemical diagnosis of hereditary hyperlipoproteinemias]. Tvorogova MG, Rozhkova TA, Alidzhanova KhG, Semenova OA, Sobolev AV, Kukharchuk VV, Titov VN. Ter Arkh; 1998 Aug 05; 70(4):9-15. PubMed ID: 9612894 [Abstract] [Full Text] [Related]
40. [Clinical research on the hypolipidemic action of a probucol preparation]. Naumova R, Kerekovska M, Goranov I, Balabanski L. Vutr Boles; 1986 Aug 05; 25(2):73-7. PubMed ID: 3716382 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]